Inversago Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Inversago Pharma's estimated annual revenue is currently $2.3M per year.
- Inversago Pharma's estimated revenue per employee is $100,500
Employee Data
- Inversago Pharma has 23 Employees.
- Inversago Pharma grew their employee count by -12% last year.
Inversago Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | CFO | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | Head Chemistry | Reveal Email/Phone |
4 | VP, Finance and Administration | Reveal Email/Phone |
5 | VP, Clinical Operations | Reveal Email/Phone |
6 | VP Pharmacology and PK | Reveal Email/Phone |
7 | Head Chemistry | Reveal Email/Phone |
8 | Senior Director Preclinical Development | Reveal Email/Phone |
9 | Senior Director Quality Assurance | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
Inversago Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.2M | 16 | 7% | N/A | N/A |
#2 | $30.2M | 150 | 1% | N/A | N/A |
#3 | $10.7M | 100 | 5% | $39.7M | N/A |
#4 | $104.3M | 519 | 22% | N/A | N/A |
#5 | $47.8M | 238 | N/A | N/A | N/A |
#6 | $15.5M | 77 | 5% | N/A | N/A |
#7 | $395.8M | 1969 | 7% | N/A | N/A |
#8 | $187.3M | 932 | 6% | N/A | N/A |
#9 | $361.6M | 1799 | 6% | N/A | N/A |
#10 | $27.5M | 137 | 0% | N/A | N/A |
What Is Inversago Pharma?
Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic nephropathy, Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG) and Type 1 Diabetes (T1D), Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
keywords:N/AN/A
Total Funding
23
Number of Employees
$2.3M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.2M | 23 | -18% | $3.7M |
#2 | $2.3M | 23 | -8% | N/A |
#3 | $3.5M | 23 | -4% | N/A |
#4 | $2.3M | 23 | N/A | N/A |
#5 | $2.3M | 23 | N/A | N/A |